Lumos Pharma Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lumos Pharma Inc (LUMO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lumos Pharma Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 162,198M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+31.7% annualized vs trailing 12 months), vs decelerating (-39.8%) for its tracked peer group.
- Growth: Lumos Pharma Inc generated 10,271.4% revenue growth year over year in Q3 2024, vs 8.7% for its tracked competitors combined.
- Profitability: Its -1,028.5% net margin compares with 9.0% for the peer group.
- Peer revenue share: Lumos Pharma Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.10M compares with $0.84M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LUMO Sales vs. its Competitors, Q3 2024
Lumos Pharma Inc reported revenue growth of 10,271.43 % year on year in Q3 2024, above its competitors' combined revenue growth of 8.70 %.
With a net margin of -1,028.51 %, Lumos Pharma Inc reported lower profitability than its competitors (8.95 %).
Lumos Pharma Inc generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Lumos Pharma Inc vs. its Competitors, Q3 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lumos Pharma Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lumos Pharma Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lumos Pharma Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 10,271.4% for Lumos Pharma Inc. Lumos Pharma Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Lumos Pharma Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lumos Pharma Inc | No | Yes | Yes | Yes |
| Competitors combined (154) | ||||
| High-Confidence Competitors (4) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 62.50 % (5 of 8) | 62.50 % (5 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LUMO Stock Performance relative to its Competitors
LUMO Stock Performance relative to High-Confidence Competitors
LUMO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 4 | Spruce Biosciences Inc | 282.9% | Outperformed |
| 5 | Praxis Precision Medicines Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lumos Pharma Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Lumos Pharma Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Lumos Pharma Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Lumos Pharma Inc | 36.14 | 2.21 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Vertex Pharmaceuticals Inc | 134,661.38 | 12,587.20 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| United Therapeutics Corporation | 22,237.73 | 3,154.50 |
| SUBTOTAL | 829,084.56 | 168,205.33 |
Sign in to see all competitors of Lumos Pharma Inc .
Sources: Lumos Pharma Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lumos Pharma Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lumos Pharma Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Eli Lilly | Named by the company | 85% |
| Novo Nordisk | Named by the company | 85% |
| F. Hoffman-La Roche Ltd./Genentech, Inc. | Named by the company | 85% |
| Pfizer Inc. | Named by the company | 85% |
| Merck Serono | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Lumos Pharma Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Lumos Pharma Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Viatris Inc | Developed Markets 57.61 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Ligand Pharmaceuticals Incorporated | Development and Licensing of Biopharmaceutical Assets 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Lumos Pharma Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lumos Pharma Inc | 36 | 95,870 | -1,518,087 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Vertex Pharmaceuticals Inc | 134,661 | 31,079,506 | 10,877,037 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| United Therapeutics Corporation | 22,238 | 2,253,214 | 936,357 |
| PEERS TOTAL | 829,048 | 844,525 | 104,280 |
Sign in to see all peers for Lumos Pharma Inc .
Lumos Pharma Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Lumos Pharma Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 64.89 % (avg) | +35.1 pp |
| Operating Margin | -1,647.57 % | industry median | -1,565.0 pp |
| EBITDA Margin | -1,582.49 % | -7.21 % (avg) | -1,575.3 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 4.92 % (avg) | -4.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Lumos Pharma Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 2.0x | 4.5x | -2.5x |
| Return on Equity | -233.03 % | industry aggregate | -243.37 % |
| Return on Invested Capital | -100.51 % | -2.95 % (avg) | -97.56 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Lumos Pharma Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -47.78 % | -19.73 % | -56.55 % | -92.50 % | -82.05 % | - | - | 34.67 % |
| Operating Margin | -253.74 % | -253.84 % | -500.55 % | -4,822.01 % | -15,656.55 % | - | -2,103.74 % | -1,785.18 % |
| Return on Invested Capital | -29.81 % | -29.79 % | -24.28 % | -23.11 % | -10.62 % | -15.45 % | -21.67 % | -42.73 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Lumos Pharma Inc's Strategic Group Map
Every company in Lumos Pharma Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Lumos Pharma Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Lumos Pharma Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Lumos Pharma Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Lumos Pharma Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Lumos Pharma Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Lumos Pharma Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Lumos Pharma Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+31.7% annualized vs trailing 12 months).
Weaknesses
- Operating margin 1,565.0 points below the industry median.
- Return on equity 243.4 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (49.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-39.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Lumos Pharma Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lumos Pharma Inc | 3.87 | 4.62 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
Sign in to see all peers for Lumos Pharma Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lumos Pharma Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lumos Pharma Inc | Q3 2024 | +10,271.4 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| PEERS TOTAL | +8.4 % | +67.6 % |
Sign in to see all peers for Lumos Pharma Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lumos Pharma Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lumos Pharma Inc | Q3 2024 | - | - |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
Sign in to see all peers for Lumos Pharma Inc .
Lumos Pharma Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lumos Pharma Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
Sign in to see all peers for Lumos Pharma Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lumos Pharma Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lumos Pharma Inc | - | 16.39 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Vertex Pharmaceuticals Inc | 30.77 | 10.70 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| United Therapeutics Corporation | 17.43 | 7.05 |
| PEERS AVERAGE | 39.99 | 4.93 |
Sign in to see all peers for Lumos Pharma Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.